Apreo Health, a clinical-stage medical device company focused on innovative treatments for severe emphysema, has announced the successful completion of an oversubscribed $130 million Series B financing round. This funding was jointly led by new investors Bain Capital Life Sciences and Norwest, with additional participation from F-Prime and Intuitive Ventures. Existing investors Lightstone Ventures and Santé Ventures also took part in the round.
The proceeds from the Series B financing will principally be used to support BREATHE-3 (Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung—Study 3), a multicenter, randomized controlled trial designed to assess the safety and efficacy of the Apreo BREATHE Airway Scaffold, a bronchoscopically implanted device intended to alleviate lung hyperinflation in patients with severe emphysema by facilitating the release of trapped air.
How the funding will be used: The funds will support regulatory activities associated with BREATHE-3, as well as initial commercialization initiatives aimed at establishing strong market potential.
KEY QUOTES:
“We are incredibly grateful for the support from this world-class syndicate of investors and their desire to partner to redefine the standard of care in emphysema. More than three million Americans are affected by severe emphysema, yet fewer than 1% receive interventional treatment—a stark reflection of limitations of currently available treatments. Our BREATHE Scaffold offers a fundamentally different approach: a novel implant designed to gently release air trapped in affected lungs, with potential for much broader adoption. This financing marks a significant milestone that enables us to complete a robustly designed pivotal trial and continue advancing toward expanded access for this severely underserved population.”
Karun Naga, CEO of Apreo Health
“Apreo is addressing one of the most underserved populations in chronic obstructive pulmonary disease (COPD) and doing so with clinical clarity and executional rigor. This is a step-change in how we approach emphysema care. The solution is both elegant in design and built for broad, scalable delivery. We’re proud to support Apreo in this next chapter.”
Zack Scott, M.D., general partner, Norwest
“We are excited to partner with Apreo at this key inflection point in the company’s evolution as it advances the BREATHE Airway Scaffold into late-stage development. The device has the potential to deliver meaningful clinical benefit to a broader patient population—addressing the significant unmet need that exists today in chronic obstructive pulmonary disease.”
Nicholas Downing, M.D., a Managing Director at Bain Capital Life Sciences
